DexCom price target lowered to $100 from $105 at BofA

BofA lowered the firm’s price target on DexCom (DXCM) to $100 from $105 and keeps a Buy rating on the shares. Q3 revenue beat the Street by $28M, but missed buyside expectations, the analyst noted. However, stepping back the firm argues that “things seem fine” and sees 2026 as derisked. DexCom is getting the 2026 Street view “in the right place to 12-13% revenue growth” ahead of the 2026 guidance in January, which removes a major investor overhang, BofA contends.